ArticleClinical ophthalmology (Auckland, N.Z.)2026
Two-Year Real-World Outcomes of Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Three-year real-world outcomes of faricimab in pretreated eyes with treatment-resistant neovascular age-related macular degeneration.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate long-term visual and anatomical outcomes of faricimab (Vabysmo Methods: This retrospective cohort study evaluated 152 eyes from 126 patients switched to faricimab. All received four loading doses, then a treat-and-extend regimen with ≥ 20-month follow-up. Primary outcomes were changes in non-refracted best-recorded visual acuity (BRVA) and central subfield thickness (CST). Secondary outcomes: fluid status, treatment interval, and safety. Results: Baseline mean BRVA was 69.91 ± 13 letters, maintained at year 2 (65.9 ± 17.1, p = 0.622). CST decreased from 301.5 ± 86.9 µm at baseline to 222.2 ± 49.2 µm at year 2 (p <0.001). Complete fluid resolution rose from 12.5% at baseline to 50.7% and 49.3% in years 1 and 2 respectively. Subretinal fluid decreased from 79% to 34% (p <0.001), while intraretinal fluid improved post-loading (30% to 18%, p=0.005) but remained detectable in 25.7% by year 2 (p=0.36). Treatment intervals were extended from 5.8 ± 1.4 weeks to 9.7 ± 3.1 weeks at year 2 (p < 0.001). By year 2, 18% of eyes achieved ≥12-week intervals; 7% achieved ≥16-week intervals. No cases of endophthalmitis, vasculitis, or retinal artery occlusion were observed, and ocular adverse events occurred in 3% of eyes. Conclusion: In treatment-resistant nAMD, switching from aflibercept 2mg to faricimab maintained vision, improved anatomical outcomes, enabled extended treatment intervals, and showed a favorable safety profile over 2 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.